Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression.

AIMP2 (aminoacyl-tRNA synthetase-interacting multifunctional protein 2) is a potent tumour suppressor that induces apoptosis in response to various oncogenic signals. AIMP2-DX2, an exon2-deleted splicing variant of AIMP2, is up-regulated in lung cancer and competitively suppresses the pro-apoptotic activity of AIMP2, resulting in tumorigenesis. In the present study we report that BC-DXI01, a synthetic compound, specifically reduces the cellular levels of AIMP2-DX2 through selective degradation of the AIMP2-DX2 mRNA transcript. We found that BC-DXI01-mediated cell death positively correlates with AIMP2-DX2 expression in the lung cancer cell lines tested. Administration of BC-DXI01 in a AIMP2-DX2-driven tumour xenograft mice model led to reduced tumour sizes and volumes of up to 60% in comparison with vehicle-treated mice group, consistent with decreases in AIMP2-DX2 transcript and protein levels. Taken together, our findings suggest that tumorigenic activity of AIMP2-DX2 can be controlled by the small chemical BC-DXI01, which can selectively suppress the AIMP2-DX2 mRNA transcript.

[1]  P. Bunn.  Worldwide overview of the current status of lung cancer diagnosis and treatment. , 2012, Archives of pathology & laboratory medicine.

[2]  D. Nam,et al.  Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. , 2012, Journal of molecular cell biology.

[3]  Thomas Hermann,et al.  Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches , 2012, Proceedings of the National Academy of Sciences.

[4]  Sunghoon Kim,et al.  Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping , 2011, Nature Reviews Cancer.

[5]  H. P. Kang,et al.  Cancer-Associated Splicing Variant of Tumor Suppressor AIMP2/p38: Pathological Implication in Tumorigenesis , 2011, PLoS genetics.

[6]  J. Viola,et al.  Osteopontin-c Splicing Isoform Contributes to Ovarian Cancer Progression , 2011, Molecular Cancer Research.

[7]  Sunghoon Kim,et al.  Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis. , 2009, Carcinogenesis.

[8]  Dae Kim,et al.  AIMP2 promotes TNFα-dependent apoptosis via ubiquitin-mediated degradation of TRAF2 , 2009, Journal of Cell Science.

[9]  Lili Wan,et al.  RNA and Disease , 2009, Cell.

[10]  Sunghoon Kim,et al.  AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53 , 2008, Proceedings of the National Academy of Sciences.

[11]  M. Garcia-Blanco,et al.  A protocol for imaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice , 2007, Nature Protocols.

[12]  Deepak Bhatnagar,et al.  Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino , 2006, Applied Microbiology and Biotechnology.

[13]  B. Brinkman,et al.  Splice variants as cancer biomarkers. , 2004, Clinical biochemistry.

[14]  Sunghoon Kim,et al.  Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation , 2003, Nature Genetics.

[15]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.